Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

Blood (2024) 144 (3): 272–282.

https://doi.org/10.1182/blood.2023022730

Published: 2024

Includes: Supplemental data

Journal Articles

Long-Term Remissions with MRD-Guided Acalabrutinib, Venetoclax and Obinutuzumab in Relapsed/Refractory CLL: Follow-up Efficacy and Circulating Tumor DNA Analysis of the CLL2-Baag Trial

Blood (2023) 142 (Supplement 1): 203.

https://doi.org/10.1182/blood-2023-173708

Published: 2023

Journal Articles

Tislelizumab Plus Zanubrutinib in Patients with Richter Transformation: Primary Endpoint Analysis of the Prospective, Multi-Center, Phase-II RT1 Trial of the German CLL Study Group

Blood (2023) 142 (Supplement 1): 204.

https://doi.org/10.1182/blood-2023-188705

Published: 2023

Journal Articles

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Blood (2023) 142 (Supplement 1): 635.

https://doi.org/10.1182/blood-2023-173709

Published: 2023

Journal Articles

Endpoint Surrogacy in Chronic Lymphocytic Leukemia: A Pooled Analysis of the German CLL Study Group

Blood (2023) 142 (Supplement 1): 1901.

https://doi.org/10.1182/blood-2023-178597

Published: 2023

Journal Articles

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/ TP53 mut

Blood (2023) 142 (11): 961–972.

https://doi.org/10.1182/blood.2023020013

Published: 2023

Includes: Supplemental data

Journal Articles

Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/ TP53 Mutation

Blood (2022) 140 (Supplement 1): 834–836.

https://doi.org/10.1182/blood-2022-163245

Published: 2022

Journal Articles

Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

Blood (2022) 139 (9): 1318–1329.

https://doi.org/10.1182/blood.2021013208

Published: 2022

Includes: Supplemental data

Journal Articles

B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide

Blood (2021) 137 (16): 2267–2271.

https://doi.org/10.1182/blood.2020008609

Published: 2021

Includes: Supplemental data

Journal Articles

BCR-Assosiated Kinase Inhibition in Relapsed/Refractory Chronic Lymphocytic Leukemia. Real World Experiences of a German Regional Clinical Register

Dietrich Kaempfe, MD, Roshanak Bob, MD, Joerg Brenn, Thomas Haverkamp, MD, Agnes Knopp, MD, Harald Stein, MD PhD Dr. h.c., Sebastian Böttcher, MD PhD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-134686

Published: 2020

Journal Articles

Severe Infections in Patients with Chronic Lymphocytic Leukemia Treated with (Immuno-)Chemotherapy: A Pooled Analysis of Gcllsg Trials

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-139242

Published: 2020

Journal Articles

Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial

Blood (2019) 134 (Supplement_1): 36.

https://doi.org/10.1182/blood-2019-125825

Published: 2019

Journal Articles

Sequential Treatment with Bendamustine, Obinutuzumab (GA101) and Ibrutinib in Chronic Lymphocytic Leukemia (CLL): Final Results of the CLL2-BIG Trial of the German CLL Study Group (GCLLSG)

Blood (2019) 134 (Supplement_1): 3046.

https://doi.org/10.1182/blood-2019-125895

Published: 2019

Journal Articles

Comparison of Overall Survival in High Risk Patients with Minimal Residual Disease after First-Line Treatment across Three Generations of Phase 3 Trials of the German CLL Study Group

Anna Maria Fink, MD, Can Zhang, PhD, Sandra Robrecht, PhD, Nadine Kutsch, MD, Moritz Fürstenau, MD, Clemens-Martin Wendtner, MD, Karl-Anton Kreuzer, MD, Michael Kneba, MD PhD, Eugen Tausch, Stephan Stilgenbauer, MD, Matthias Ritgen, MD, Sebastian Böttcher, MD, Kirsten Fischer, MD, Michael Hallek, MD, Barbara F. Eichhorst, MD

Blood (2019) 134 (Supplement_1): 3040.

https://doi.org/10.1182/blood-2019-125063

Published: 2019

Journal Articles

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

Anton W. Langerak, Matthias Ritgen, Valentin Goede, Sandra Robrecht, Jasmin Bahlo, Kirsten Fischer, Michael Steurer, Marek Trněný, Stephen P. Mulligan, Ulrich J. M. Mey, Kerstin Trunzer, Günter Fingerle-Rowson, Kathryn Humphrey, Stephan Stilgenbauer, Sebastian Böttcher, Monika Brüggemann, Michael Hallek, Michael Kneba, Jacques J. M. van Dongen

Blood (2019) 133 (5): 494–497.

https://doi.org/10.1182/blood-2018-03-839688

Published: 2019

Includes: Supplemental data

Journal Articles

Tocilizumab to Prevent Infusion-Related Events in Patients with Chronic Lymphocytic Leukemia and Co-Morbidities Treated with Obinutuzumab and Chlorambucil: Results from the Randomized Phase Ib GALACTA Trial

Ciara Louise Freeman, MRCP, MSc, FRCPath, MBBChir, Sebastian Böttcher, Javier De la Serna, Julio Delgado, Franca Falzetti, Marco Gobbi, MD, Sandra Lejniece, Maria Chiara Di Bernardo, Navita L Mallalieu, Tina Nielsen, Andrea Knapp, John G. Gribben

Blood (2018) 132 (Supplement 1): 4419.

https://doi.org/10.1182/blood-2018-99-118238

Published: 2018

Journal Articles

Residual Abdominal Lymphadenopathy after Intensive Frontline Chemoimmunotherapy Is Associated with Inferior Outcome Regardless of MRD Status in Advanced Chronic Lymphocytic Leukemia (CLL)

Moritz Fürstenau, MD, Jasmin Bahlo, PhD, Anna-Maria Fink, MD, Elisabeth Lange, Peter Dreger, MD, Martin Dreyling, MD PhD, Georg Hess, Matthias Ritgen, MD, Michael Kneba, Hartmut Döhner, MD, Stephan Stilgenbauer, MD PhD, Clemens-Martin Wendtner, Valentin Goede, MD, Kirsten Fischer, MD, Sebastian Böttcher, Michael Hallek, Barbara Eichhorst

Blood (2018) 132 (Supplement 1): 4430.

https://doi.org/10.1182/blood-2018-99-113280

Published: 2018

Journal Articles

Real Life Dates of Chronic Lymphocytic Leukemia (CLL) in Germany. Interim Analysis of 234 Consecutively New Diagnosed Patients in a German Epidemiological-Clinical Register

Dietrich Kämpfe, MD, Harald Stein, MD PhD Dr. h.c., Roshanak Bob, MD, Sebastian Böttcher, Joerg Brenn, Agnes Knopp, MD, Thomas Haverkamp, MD, Christoph Schulte, MD, Detlef Haase, MD PhD

Blood (2018) 132 (Supplement 1): 2264.

https://doi.org/10.1182/blood-2018-99-110618

Published: 2018

Journal Articles

Minimal Residual Disease Status with Venetoclax Monotherapy Is Associated with Progression-Free Survival in Chronic Lymphocytic Leukemia

William G. Wierda, MD PhD, Andrew W. Roberts, MBBS, PhD, Paolo Ghia, MD PhD, Jennifer R. Brown, MD PhD, Stephan Stilgenbauer, Florence Cymbalista, MD, Nicole Lamanna, MD, John F. Seymour, MBBS, PhD, Sebastian Böttcher, MD, Madlaina Breuleux, PhD DAS, Brenda Chyla, Lang Zhou, PhD, Jacqueline Nielsen, PhD, Su Young Kim, MD PhD, Jalaja Potluri, MD, Johnathan C. Maher, PhD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath

Blood (2018) 132 (Supplement 1): 3134.

https://doi.org/10.1182/blood-2018-99-110183

Published: 2018

Journal Articles

A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL

Natalie Dimier, Paul Delmar, Carol Ward, Rodica Morariu-Zamfir, Günter Fingerle-Rowson, Jasmin Bahlo, Kirsten Fischer, Barbara Eichhorst, Valentin Goede, Jacques J. M. van Dongen, Matthias Ritgen, Sebastian Böttcher, Anton W. Langerak, Michael Kneba, Michael Hallek

Blood (2018) 131 (9): 955–962.

https://doi.org/10.1182/blood-2017-06-792333

Published: 2018

Includes: Supplemental data

NARROW

Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

Long-Term Remissions with MRD-Guided Acalabrutinib, Venetoclax and Obinutuzumab in Relapsed/Refractory CLL: Follow-up Efficacy and Circulating Tumor DNA Analysis of the CLL2-Baag Trial

Tislelizumab Plus Zanubrutinib in Patients with Richter Transformation: Primary Endpoint Analysis of the Prospective, Multi-Center, Phase-II RT1 Trial of the German CLL Study Group

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Endpoint Surrogacy in Chronic Lymphocytic Leukemia: A Pooled Analysis of the German CLL Study Group

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/ TP53 mut

Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/ TP53 Mutation

Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide

BCR-Assosiated Kinase Inhibition in Relapsed/Refractory Chronic Lymphocytic Leukemia. Real World Experiences of a German Regional Clinical Register

Severe Infections in Patients with Chronic Lymphocytic Leukemia Treated with (Immuno-)Chemotherapy: A Pooled Analysis of Gcllsg Trials

Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial

Sequential Treatment with Bendamustine, Obinutuzumab (GA101) and Ibrutinib in Chronic Lymphocytic Leukemia (CLL): Final Results of the CLL2-BIG Trial of the German CLL Study Group (GCLLSG)

Comparison of Overall Survival in High Risk Patients with Minimal Residual Disease after First-Line Treatment across Three Generations of Phase 3 Trials of the German CLL Study Group

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

Tocilizumab to Prevent Infusion-Related Events in Patients with Chronic Lymphocytic Leukemia and Co-Morbidities Treated with Obinutuzumab and Chlorambucil: Results from the Randomized Phase Ib GALACTA Trial

Residual Abdominal Lymphadenopathy after Intensive Frontline Chemoimmunotherapy Is Associated with Inferior Outcome Regardless of MRD Status in Advanced Chronic Lymphocytic Leukemia (CLL)

Real Life Dates of Chronic Lymphocytic Leukemia (CLL) in Germany. Interim Analysis of 234 Consecutively New Diagnosed Patients in a German Epidemiological-Clinical Register

Minimal Residual Disease Status with Venetoclax Monotherapy Is Associated with Progression-Free Survival in Chronic Lymphocytic Leukemia

A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only